Anti-KRAS antibody
| Name | Anti-KRAS antibody |
|---|---|
| Supplier | Abcam |
| Catalog | ab84573 |
| Prices | $378.00 |
| Sizes | 50 µg |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Applications | WB IHC-P |
| Species Reactivities | Human, Zebrafish, Mouse, Rat, Rabbit, Horse, Chicken, Guinea Pig, Bovine, Cat, Dog, Pig, Yeast, Drosophila |
| Antigen | Immunogen sequence is 100% homologous to human KRAS, NRAS and HRAS |
| Description | Rabbit Polyclonal |
| Gene | KRAS |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
Anti-KRAS antibody (ab84573) at 1 µg/ml + Human fetal heart lysateSecondaryHRP conjugated anti-Rabbit IgG at 1/50000 dilution
ab84573 at 5 µg/ml staining KRAS in Human placenta by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections).
ab84573 at 5 µg/ml staining KRAS in Human placenta by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections).
All lanes : Anti-KRAS antibody (ab84573) at 1 µg/mlLane 1 : MarkerLane 2 : Zebrafish brain homogenate at 20 µgLane 3 : Zebrafish heart homogenate at 20 µgSecondaryGoat polyclonal to Rabbit IgG – H&L – Pre-Adsorbed (HRP) at 1/6000 dilutiondeveloped using the ECL techniquePerformed under reducing conditions.
developed using the ECL techniquePerformed under reducing conditions.
Product References
PTTG acts as a STAT3 target gene for colorectal cancer cell growth and motility. - PTTG acts as a STAT3 target gene for colorectal cancer cell growth and motility.
Zhou C, Tong Y, Wawrowsky K, Melmed S. Oncogene. 2014 Feb 13;33(7):851-61.
Mutant KRAS is a druggable target for pancreatic cancer. - Mutant KRAS is a druggable target for pancreatic cancer.
Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20723-8. doi: